Chief Financial Officer
Paul Brannelly has served as our chief financial officer since June 2021. Prior to joining Ribon, he served as the chief financial officer of Collegium Pharmaceutical, Inc. from February 2015 to May 2021. Prior to Collegium, Mr. Brannelly served in senior financial leadership roles at Karyopharm Therapeutics, Inc. and Verastem, Incorporated. Earlier in his career, Mr. Brannelly was chief financial officer of Longwood Fund, a healthcare dedicated venture capital fund, and also held senior financial management roles with Sirtris Pharmaceuticals (acquired by GlaxoSmithKline), CombinatoRx and Dyax. With more than 20 years in the biopharmaceutical industry, Mr. Brannelly has raised $1.4 billion in debt and equity. He holds a Bachelors in Business Administration in Accounting from the University of Massachusetts, Amherst and was a Certified Public Accountant.